Illumina (ILMN) Q3 2026 Earnings Call: Q&A Summary

Q: Tycho Peterson from Jefferies asked about clinical consumable trends, specifically regarding stocking orders and if low double-digit growth is the right baseline for next year.

A: Jacob Thaysen stated that clinical performance remains strong, with 14% to 15% growth in the third quarter, and they expect this to continue. Ankur Dhingra added that Q4 consumables guidance was raised due to strong instrument placements.

Q: Vijay Kumar from Evercore ISI asked if the long-range plan targets remain intact and if instruments could become a headwind next year.

A: Jacob Thaysen noted that the company will provide full 2027 guidance in the fourth quarter. He highlighted a healthy market environment, particularly in clinical, and noted that the company is moving into growth as the NovaSeq X transition concludes.

Q: Doug Schenkel from UBS asked if there was any pull-forward in NovaSeq X demand and how the mix of demand breaks down between capacity expansion and replacements.

A: Jacob Thaysen stated there was no pull-forward, attributing demand to healthy market conditions and sequencing-intensive assays. He emphasized that customers view the NovaSeq X as the platform for the future.

Q: Puneet Souda from Leerink asked if the sequencing consumable dynamic is driven by lower cost-per-gigabase elasticity and if the high single-digit growth framework for 2027 is intact.

A: Jacob Thaysen explained that the transition to the NovaSeq X generates more volume, which drives growth. He noted they are willing to discuss pricing for large volume commitments and confirmed the 2027 high single-digit growth target remains on track.

Q: Subhalaxmi Nambi from Guggenheim asked if new products still contribute 1 to 2 points of growth and if 25% operating margin is the right launch point for 2027.

A: Jacob Thaysen confirmed that new products and data are contributing to growth. He noted that the company has improved margins by 400 basis points despite headwinds and expects further improvement in 2027.

Q: Luke Sergott from Barclays asked how clinical sequencing growth plays out with liquid biopsy players and the NovaSeq X transition.

A: Jacob Thaysen and Ankur Dhingra explained that the NovaSeq X transition is a razor-blade model where placements drive future revenue. Clinical growth remains strong, supported by a rich pipeline of clinical trials.

Q: Dan Arias from Stifel asked how genome pricing affects the AI and virtual cell opportunity and if price elasticity needs to be revisited.

A: Jacob Thaysen stated the AI opportunity is about creating large, standardized data sets rather than just genome pricing. He emphasized that Illumina is well-positioned to lead this through its broad portfolio.

Q: David Westenberg from Piper Sandler asked about the magnitude of Illumina's participation in large clinical projects.

A: Jacob Thaysen and Ankur Dhingra noted they work closely with customers to align growth. Ankur Dhingra added that U.S. clinical growth is well above 14%.

Q: Kyle Mikson from Canaccord Genuity asked if there is upside to high single-digit growth and if double-digit growth is possible while expanding margins.

A: Jacob Thaysen said upside is possible, but they want to demonstrate high single-digit growth first. He cited the clinical market and the return of research as key drivers.

Q: Dan Lee from RBC asked when BioInsight will become visible in the P&L.

A: Jacob Thaysen and Ankur Dhingra stated they expect to provide color on the Billion Cell Atlas and other AI applications in 2027.

Q: Casey Woodring from JPMorgan asked about the impact of the extra selling week in Q4, potential budget flushes, and the status of the business in China.

A: Ankur Dhingra stated the extra week has minimal revenue impact and they do not anticipate a specific budget flush. Jacob Thaysen added they are committed to China and are working to understand recent trade news.

Q: Daniel Brennan from Cowen asked if the AI opportunity is more service-based or instrument-based and if the Billion Cell Atlas is more single-cell or whole genome.

A: Jacob Thaysen and Ankur Dhingra explained it will be a blend of service and instrument demand. The Billion Cell Atlas involves combinations of whole genome, proteomics, single-cell, and transcriptomics.

Q: David Westenberg from Piper Sandler asked for a follow-up on China growth and the go-forward strategy.

A: Jacob Thaysen reiterated their commitment to China, focusing on supporting customers and driving innovation.

Q: Tycho Peterson from Jefferies asked for elaboration on operating leases and potential spillover to clinical.

A: Ankur Dhingra explained that operating leases and reagent rental models are available globally, with demand growing in mid-sized clinical labs.